Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients

Diabetes Care

Volumn 22, Issue 7, 1999, Pages 1137-1143

  Toft Nielsen, Mai Britt ^a,b   Madsbad, Sten ^a   Holst, Jens Juul ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; AGED; APPETITE; ARTICLE; BASAL METABOLIC RATE; BLOOD PRESSURE; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; APPETITE; APPETITE DEPRESSANTS; BLOOD GLUCOSE; BLOOD PRESSURE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; ENERGY INTAKE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INSULIN; LIPIDS; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PILOT PROJECTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS;

EID: 0032976939     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.7.1137     Document Type: Article

References (38)

1. Alberti KGMM, Zimmet P, DeFronzo RA, Keen H: International Textbook of Diabetes Mellitus. 2nd ed. Chichester, U.K., Wiley, 1995
2. Holst JJ, Ørskov AC, Schwartz TW, Nielsen OV: Truncated glucagon-like peptide-1, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174, 1987
3. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 (proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum and stomach. Endocrinology 123:2009-2013, 1988
4. Hvidberg A, Nielsen M-B T, Hilsted J, Ørskov C, Holst JJ: Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43:104-108, 1994
5. Larsson H, Holst JJ, Ahrén B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422, 1997
6. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
7. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520, 1998
8. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-dependent glucose disposal. J Clin Invest 93:2263-2266, 1994
9. Toft-Nielsen M, Madsbad S, Holst JJ: The effect of glucagon-like peptide-1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556, 1996
10. Ørskov L, Holst JJ, Møller J, Ørskov C, Møller N, Alberti KGMM, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232, 1996
11. Nauck MA, Kleine N, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
12. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 236:1316-1322, 1992
13. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
14. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
15. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
16. Toft-Nielsen MB, Madsbad S, Holst JJ: IV glucagon-like peptide-1 (GLP-1) lowers blood glucose levels in NIDDM patients regardless of fasting glucose, BMI, and insulin capacity (Abstract). Diabetes 46 (Suppl. 1):189A, 1997
17. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck M: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
18. Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
19. Deacon CF, Nauck MA, Toft-Nielsen MB, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
20. Gutniak MK, Larsson H, Sanders SW, Juneskans OT, Holst JJ, Ahrén B: GLP-1 tablet in type 2 diabetes in fasting and post-prandial conditions. Diabetes Care 20:1874-1879, 1997
21. Raben A, Tagliabue A, Astrup A: The reproducibility of subjective appetite scores. Br J Nutr 73:517-530, 1995
22. Ørskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in plasma from non-insulin dependent diabetics and non-diabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 87:415-423, 1991
23. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539, 1994
24. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B: Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 19:843-848, 1996
25. Miles J, Glasscock R, Aikens J, Gerich J, Haymond M: A microflourometric method for the determination of free fatty acids in plasma. J Lipid Res 24:96-99, 1983
26. Larsen J, Jallad N, Damsbo P: One-week continuous infusion of GLP-1(7-37) improves the glycaemic control in NIDDM (Abstract). Diabetes 45 (Suppl. 2):233A, 1996
27. Larsen J, Damsbo P: GLP-1 must be present continuously in order to obtain a good glycaemic control in NIDDM (Abstract). Diabetes 46 (Suppl. 1):186A, 1997
28. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044, 1994
29. Todd JF, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
30. Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Göke B, Katschinski M: Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1 (7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 156:177-186, 1998
31. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
32. Creutzfeldt WOC, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA: Glucagono-static actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586, 1996
33. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Rössner S, Hellström PM: Energy intake and appetite is suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obesity 23:304-311, 1999
34. Kelley DE: Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 3:366-377, 1995
35. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S: The antidiabetic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19:1200-1206, 1996
36. Richter G, Feddersen O, Wagner U, Göke R, Göke B: GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 265:L374-L381, 1993
37. Barragán JM, Rodriguez RE, Blázquez E: Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266:E459-E466, 1994
38. Barragán JM, Rodríguez RE, EngJ, Bláquez E: Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67:63-68, 1996